If exercise in the early stage of the T2DM can delay the progressive loss of endogenous GLP-1R levels, it may be a novel strategy for glycemic lowering prior to pharmacological treatments and improving the effects of incretin treatment. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.